LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Review

Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis

Elin Hoffmann Dahl, Prof Placide Mbala, Sylvain Juchet, Prof Abdoulaye Touré, Alice Montoyo, Beatrice Serra, Richard Kojan, Eric D'Ortenzio, Prof Bjorn Blomberg, Marie Jaspard
Download
Download
Summary Points

Ebola virus disease kills more than half of people infected. Since the disease is transmitted via close human contact, identifying individuals at the highest risk of developing the disease is possible on the basis of the type of contact (correlated with viral exposure). Different candidates for post-exposure prophylaxis (PEP; ie, vaccines, antivirals, and monoclonal antibodies) each have their specific benefits and limitations, which we discuss in this Viewpoint. Approved monoclonal antibodies have been found to reduce mortality in people with Ebola virus disease. As monoclonal antibodies act swiftly by directly targeting the virus, they are promising candidates for targeted PEP in contacts at high risk of developing disease. This intervention could save lives, halt viral transmission, and, ultimately, help curtail outbreak propagation. We explore how a strategic integration of monoclonal antibodies and vaccines as PEP could provide both immediate and long-term protection against Ebola virus disease, highlighting ongoing clinical research that aims to refine this approach, and discuss the transformative potential of a successful PEP strategy to help control viral haemorrhagic fever outbreaks.

Subject Area
Ebolaoutbreaksinfections, other
DOI
10.1016/S2214-109X(24)00255-9
Published Date
10-Sep-2024
PubMed ID
39270687
Languages
English
Journal
The Lancet Healthy Longevity
Volume / Issue / Pages
Volume 12, Issue 10, Pages e1730 - e1736
Dimensions Badge